The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: An update from MD Anderson Cancer Center.
 
Marie-Andree Forget
No Relationships to Disclose
 
Cara L. Haymaker
Research Funding - Idera; Nektar
 
Kenneth R. Hess
Travel, Accommodations, Expenses - Angiochem
 
Jason Roszik
No Relationships to Disclose
 
Scott Eric Woodman
No Relationships to Disclose
 
Orenthial J. Fulbright
No Relationships to Disclose
 
Arely Wahl
No Relationships to Disclose
 
Esteban Flores
No Relationships to Disclose
 
Shawne T. Thorsen
No Relationships to Disclose
 
Rene J. Tavera
No Relationships to Disclose
 
Renjith Ramachandran
Stock and Other Ownership Interests - Immune Pharmaceuticals; Sangamo Bioscience; Valeant Pharmaceuticals International
 
Rodabe Navroze Amaria
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst)
 
Patrick Hwu
Stock and Other Ownership Interests - immatics; Lion Biotechnologies
Consulting or Advisory Role - Lion Biotechnologies
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst)
 
Chantale Bernatchez
Employment - Lexicon (I)
Stock and Other Ownership Interests - Lexicon (I)
Consulting or Advisory Role - Lion Biotechnologies
Research Funding - Idera; Nektar
Patents, Royalties, Other Intellectual Property - Patent pending on BTLA as a marker for better CD8 T cells for adoptive immunotherapy